Literature DB >> 18672471

Fampridine for MS responders: clinically relevant or hypothesis generating?

Richard J Kryscio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18672471     DOI： 10.1212/01.wnl.0000326215.57202.2d

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

Review 1.  [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].

Authors:  L Husseini; V I Leussink; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

2.  A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.

Authors:  Andrew D Goodman; Theodore R Brown; Randall T Schapiro; Michael Klingler; Ron Cohen; Andrew R Blight
Journal:  Int J MS Care       Date:  2014

3.  Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training.

Authors:  Prudence Plummer
Journal:  Int J MS Care       Date:  2016 May-Jun

4.  Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.

Authors:  Keith C Hayes
Journal:  Neuropsychiatr Dis Treat       Date:  2011-04-28       Impact factor: 2.570
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.